RecruitingNot Applicable

Preventing Chemotherapy-induced Peripheral Neuropathy Using PRESIONA Exercise Program

Spain25 participantsStarted 2021-01-01

Plain-language summary

The aim of this study is to determinate if therapeutic exercise with blood flow restriction (BFR) during neoadjuvant chemotherapy potentialy neurotoxic could prevent the onset of chemotherapy induced peripheral neuropathy (CIPN) comparing to usual care.

Who can participate

Age range18 Years – 70 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18 years or older * HER2+ breast cancer diagnosis * On the waiting list to anticancer medical treatment (taxanes-based neoadjuvant chemotherapy) Exclusion Criteria: * Previous diagnosis of cancer * Pregnant * Cardiac pathology * No symptoms or pathology that could be confused with neuropathy or related to diabetes * No recommendation from oncologist for therapeutic exercise practice

What they're measuring

Patient-reported CIPN symptoms

Timeframe: Change from Baseline to 12 weeks (after intervention)

Trial details

NCT IDNCT04652609

SponsorUniversidad de Granada

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-01-01

Contact for this trial

Irene Cantarero-Villanueva, PhD

958248764 irenecantarero@ugr.es

View on ClinicalTrials.gov More Breast Neoplasm trials